Solara Active Pharma Sciences Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/b3eur9fh5fvaqbvxwkazxjj5.pdf

Key Takeaways


Vizag Facility: The Growth Catalyst

Devendra: "We are very upbeat in terms of Solara returning to its historical levels, and you will see this from the second half of this financial year."

Margin & Profitability Trajectory

Devendra: "We want to get back to our historical levels. So yes, we have plans where we will be at high teens, or we'll be at 20%. But it's going to be a combination of just not FY '24, but it will be also FY '25 because if you look at the year as a whole, when you look at an outgoing second half and more so with the Q4 of FY '24, then we will be in the high teens number."

Balance Sheet & Working Capital

Hariharan: "Actually, the number of days is 200 days plus, and it will come to 150 days by FY '24."

Regulatory & Product Pipeline

Devendra: "In the polymer-based chemistry as a pure-play API company, right? There are only two companies who have current approved DMS and selling polymer-based products and one is Solara."

Strategic Direction Under New Leadership

Purohit: "I'm excited to be part of Solara 3.0 growth journey."

Guidance & Commitments

CommitmentSpecificsTimeline
Gross margin sustainability50% level sustainable for the full year, with quarterly fluctuationsFY24
Vizag capacity utilizationCross 60% utilizationQ4 FY24
Working capital daysReduce from 200+ days to 150 daysBy FY24
Net debt reductionMarginal reduction, approximately 10% from ₹1,000 croresFY24
EBITDA marginReach high teens percentageQ4 FY24
EBITDA margin full recoveryReturn to historical levels of high teens or 20%Combination of FY24 and FY25
Cuddalore reinspectionUS FDA inspection expectedFY24, if not in first half
China Ibuprofen supply from VizagQualify Vizag as additional supply siteFY24
CIP benefit realizationFull flow-through of cost improvement program benefitsFrom Q2 FY24
Revenue and EBITDA growthYear-on-year improvement, in similar lines of FY23 or betterFY24

Key Metrics

MetricQ4 FY23
Revenue growth5% YoY
Gross margin50.3%
EBITDA₹51.5 cr
FY23 revenue₹1,466 cr, growth of 14% YoY
FY23 gross margin46%
FY23 operating EBITDA₹226.8 cr, 15.5% margin
FY23 reported EBITDA₹150.7 cr, growth of 63% over last year
New product revenue share14% of total sales
Market extensions in Q43 market extensions for 3 existing products
Vizag capacity utilization targetMore than 60% by Q4 FY24
Net debt to EBITDA6% in FY23, down from 10 plus in FY22
Gross debt reduction in FY23₹23 cr
Net current assets reduction in FY23₹63 cr
Working capital days200+ days, expected to reduce to 150 days by FY24
Maintenance capex guidance₹70 cr to ₹80 cr for FY24
Regulated market sales share70% to 75% historically